Pfizer submits data on COVID-19 vaccine for children ages 5-11 to FDA

Published



Pfizer and BioNTech announced that they had submitted data to the Food and Drug Administration showing that their COVID-19 vaccine was safe and effective for children between the ages of 5 and 11.

The vaccine demonstrated a “favorable safety profile and elicited robust neutralizing antibody response” in children who had received two doses, according to the companies. The clinical trial included 2,268 participants.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.